T1	Participants 56 93	postmenopausal breast cancer patients
T2	Participants 432 509	metastatic breast cancer patients with previous exposure to endocrine therapy
T3	Participants 1056 1183	primary tumor tissue from patients who participated in a randomized trial of adjuvant tamoxifen (1-3 years) versus observation.
T4	Participants 2071 2185	CONCLUSIONS Patients whose tumor expresses p-p70S6K, as a marker of downstream PI3K and/or MAPK pathway activation
